Devyser launches Genomic Blood Typing assay: All blood groups, one simple test
Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation...
In this paper Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital and Chief Medical Officer at Devyser explains that, monitoring for mixed chimerism in patients after HSCT has in several studies been shown to be of
clinical importance. The main purpose of the assay is
to verify engraftment and subsequently monitor for
the presence of MRD and potentially early detection
of possible relapse.
In this paper Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital and Chief Medical Officer at Devyser explains that, monitoring for mixed chimerism in patients after HSCT has in several studies been shown to be of
clinical importance. The main purpose of the assay is
to verify engraftment and subsequently monitor for
the presence of MRD and potentially early detection
of possible relapse.
Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation...
Read More
Devyser, a pioneer in advanced genetic testing solutions, proudly announces the global launch of...
Read More
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a significant...
Read More
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation...
Read More